An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM

CompletedOBSERVATIONAL
Enrollment

314

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

April 30, 2021

Study Completion Date

May 1, 2021

Conditions
Invasive Fungal Infection
Interventions
DEVICE

other antifungal agents,breathing machine

If treatment failure for patients in group A,group B,group C and group D,change other antifungal agents(Amphotericin B for Injection,25mg,North China Pharmaceutical Co., Ltd or Caspofungin Acetate for lnjection,50mg and 70mg Cancidas®). Mechanical ventilation((EVITA 4, Dräger Medical Equipment (Shanghai) Co.,Ltd) was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of antifungal agents therapy.

Trial Locations (1)

41

Zhengzhou Central Hospital affiliated to Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

People's Hospital of Zhengzhou University

OTHER

NCT04004078 - An Individualized Administration Research of Voriconazole Based on CYP2C19 Gene Polymorphism and TDM | Biotech Hunter | Biotech Hunter